# SHPH (Shuttle Pharmaceuticals Holdings, Inc.) - SEC EDGAR Financial Statements

> Shuttle Pharmaceuticals Holdings, Inc. reported $22.81M in total assets and a net loss of $10.26M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/SHPH
- Markdown: https://convexityos.com/fundamentals/SHPH.md
- SEC CIK: 0001757499
- Reporting currency: USD
- Latest filing period: June 30, 2026
- Last synced: Nov 21, 2026, 05:02 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001757499&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$11.22M | Operating profit |
| Net Income | FY 2025 | -$10.26M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$10.11 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Jun 30, 2026 | $90K | Total debt: $195K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Research & Development | $4.05M | $3.62M | $3.52M | $1.15M | $1.02M |
| Total Operating Expenses | $11.92M | $7.70M | $5.89M | $2.55M | $1.74M |
| **Operating Income** | -$11.92M | -$7.70M | -$5.89M | -$2.55M | -$1.74M |
| **EBITDA** | -$11.63M | -$7.69M | -$5.89M | -$2.55M | -$1.74M |
| Interest Income | $1.1K | $38K | $79K | -- | -- |
| Interest Expense | -- | -- | $2.12M | $918K | $3.8K |
| Income Before Tax | -- | -- | -$6.59M | -$3.03M | -$1.15M |
| **Net Income** | -$11.72M | -$9.14M | -$6.59M | -$3.03M | -$1.15M |
| Basic EPS | -$71.60 | -$796.50 | -$882.50 | -$580.00 | -$240.00 |
| **Diluted EPS** | -$71.60 | -$826.00 | -$882.50 | -$580.00 | -- |
| Basic Shares Outstanding | 163.8K | 11.5K | 7.5K | 5.2K | 4.7K |
| Diluted Shares Outstanding | 163.8K | 11.5K | 7.5K | 5.2K | -- |

### Income Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $56K | $267K | $512K | $943K | $1.03M | $1.57M | $986K | $1.40M |
| Total Operating Expenses | $3.95M | $2.22M | $2.79M | $2.27M | $3.91M | $2.95M | $1.78M | $3.05M |
| **Operating Income** | -$3.95M | -$2.22M | -$2.79M | -$2.27M | -$3.91M | -$2.95M | -$1.78M | -$3.05M |
| **EBITDA** | -$3.32M | -$1.58M | -- | -$2.27M | -$3.91M | -$2.95M | -$1.78M | -$3.05M |
| Interest Income | $90 | $209 | -- | $486 | $81 | -- | $3 | $2.5K |
| **Net Income** | -$3.15M | -$2.15M | -$2.61M | -$2.35M | -$3.71M | -$3.05M | -$1.60M | -$3.78M |
| Basic EPS | -$3.10 | -$4.30 | -- | -$10.50 | -$32.91 | -$76.00 | -- | -$398.30 |
| **Diluted EPS** | -$3.10 | -$4.30 | -- | -$10.50 | -$32.91 | -$76.00 | -- | -$398.30 |
| Basic Shares Outstanding | 1.0M | 503.2K | -- | 223.4K | 112.6K | 40.2K | -- | 9.5K |
| Diluted Shares Outstanding | 1.0M | 503.2K | -- | 223.4K | 112.6K | 40.2K | -- | 9.5K |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $334K | $1.92M | $2.58M | $8.42M | $505K |
| Short-Term Investments | -- | -- | $2.89M | -- | -- |
| **Cash & Short-Term Investments** | $334K | $1.92M | $5.46M | $8.42M | $505K |
| **Total Current Assets** | $503K | $2.21M | $5.59M | $8.58M | $510K |
| Property, Plant & Equipment, Net | $17K | $19K | $25K | $13K | $19K |
| Intangible Assets | $9.84M | -- | -- | -- | -- |
| Other Non-Current Assets | -- | -- | -- | $6.5K | -- |
| **Total Non-Current Assets** | $9.97M | $295K | $359K | $75K | $142K |
| **Total Assets** | $10.48M | $2.51M | $5.95M | $8.65M | $652K |
| Other Current Liabilities | $4.44M | -- | -- | -- | -- |
| **Total Current Liabilities** | $7.97M | $1.53M | $1.04M | $976K | $2.22M |
| Long-Term Debt | -- | -- | -- | -- | $91K |
| **Total Non-Current Liabilities** | $255K | $263K | $854K | $0 | $62K |
| **Total Liabilities** | $8.22M | $1.80M | $1.90M | $976K | $2.28M |
| **Total Debt (incl. Leases)** | $232K | $299K | $357K | $63K | $220K |
| Common Stock | $2 | $2 | $20 | $136 | $93 |
| Retained Earnings | -$46.30M | -$34.58M | -$25.43M | -$8.89M | -$5.80M |
| **Total Stockholders' Equity** | $2.25M | $709K | $4.06M | $7.68M | -$1.63M |
| Total Equity | $2.25M | $709K | $4.06M | $7.68M | -$1.63M |

### Balance Sheet (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $90K | $1.09M | $334K | $2.09M | $4.82M | $4.51M | $1.92M | $157K |
| **Cash & Short-Term Investments** | $90K | $1.09M | $334K | $2.09M | $4.82M | $4.51M | $1.92M | $157K |
| **Total Current Assets** | $396K | $2.46M | $503K | $3.27M | $5.19M | $4.96M | $2.21M | $361K |
| Property, Plant & Equipment, Net | $15K | $16K | $17K | $18K | $19K | $18K | $19K | $21K |
| Intangible Assets | $8.65M | $9.24M | $9.84M | -- | -- | -- | -- | -- |
| **Total Non-Current Assets** | $22.41M | $9.35M | $9.97M | $277K | $313K | $351K | $295K | $312K |
| **Total Assets** | $22.81M | $11.81M | $10.48M | $3.54M | $5.50M | $5.31M | $2.51M | $674K |
| Other Current Liabilities | -- | -- | $4.44M | -- | -- | -- | -- | -- |
| **Total Current Liabilities** | $3.48M | $8.31M | $7.97M | $1.96M | $1.69M | $1.78M | $1.53M | $1.66M |
| **Total Non-Current Liabilities** | $148K | $157K | $255K | $184K | $206K | $243K | $263K | $330K |
| **Total Liabilities** | $3.63M | $8.46M | $8.22M | $2.15M | $1.90M | $2.02M | $1.80M | $1.99M |
| **Total Debt (incl. Leases)** | $195K | $214K | $232K | $250K | $267K | $283K | $299K | $314K |
| Common Stock | $9 | $57 | $2 | $13 | $11 | $63 | $2 | $29 |
| Retained Earnings | -$51.60M | -$48.45M | -$46.30M | -$43.68M | -$41.34M | -$37.63M | -$34.58M | -$32.98M |
| **Total Stockholders' Equity** | $19.18M | $3.35M | $2.25M | $1.39M | $3.61M | $3.29M | $709K | -$1.32M |
| Total Equity | $19.18M | $3.35M | $2.25M | $1.39M | $3.61M | $3.29M | $709K | -$1.32M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$11.72M | -$9.54M | -$6.59M | $1.69M | -$1.15M |
| Depreciation & Amortization | $290K | $5.5K | $6.8K | $6.0K | $6.2K |
| Stock-Based Compensation | $933K | $260K | $182K | $404K | $910K |
| Change in Payables | -- | -- | -- | -$383K | $311K |
| **Operating Cash Flow** | -$9.48M | -$7.33M | -$5.58M | -$2.71M | -$300K |
| Capital Expenditure | -- | -- | -$19K | -- | -- |
| **Free Cash Flow** | -- | -- | -$5.60M | -- | -- |
| Purchases of Investments | -- | -$44K | -$3.00M | -- | -- |
| **Investing Cash Flow** | -$3.06M | $2.92M | -$2.83M | -- | -- |
| Common Stock Issued | -- | $3.99M | -- | $10.02M | -- |
| **Financing Cash Flow** | $10.95M | $3.76M | $2.57M | $10.62M | $688K |
| **Net Change in Cash** | -$1.59M | -$656K | -$5.84M | $7.91M | $388K |

### Cash Flow Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$3.15M | -$2.15M | -$2.61M | -$2.30M | -$3.80M | -$3.00M | -$1.60M | -$3.78M |
| Depreciation & Amortization | $633K | $633K | -- | $1.0K | -$979 | $1.0K | $1.8K | $793 |
| Stock-Based Compensation | -$7.5K | $35K | $215K | $134K | $47K | $537K | $32K | $45K |
| **Operating Cash Flow** | -$568K | -$2.42M | -$973K | -$2.63M | -$3.36M | -$2.53M | -$2.69M | -$2.00M |
| Purchases of Investments | -- | -- | -- | -- | -- | -- | $0 | -$7.6K |
| **Investing Cash Flow** | -$5.43M | -$36K | -- | -- | -- | -- | $0 | $1.66M |
| Common Stock Issued | $0 | $3.23M | -- | -$4.08M | $4.08M | $5.41M | -- | -- |
| **Financing Cash Flow** | $5.00M | $3.21M | $2.27M | -$96K | $3.66M | $5.12M | $4.45M | -$197K |
| **Net Change in Cash** | -$1000K | $756K | -$1.76M | -$2.72M | $305K | $2.59M | $1.76M | -$539K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -519.9% | -1289.5% | -162.6% | -39.4% | -- |
| Return on Assets (ROA) | -111.9% | -364.9% | -110.8% | -35.0% | -176.8% |
| Current Ratio | 0.06x | 1.44x | 5.37x | 8.79x | 0.23x |
| Quick Ratio | 0.04x | 1.25x | 5.24x | 8.63x | 0.23x |
| Debt to Equity | 0.10x | 0.42x | 0.09x | 0.01x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -53.5% | -323.4% | -519.9% | -767.9% | -336.8% | -318.6% | -1289.5% | -- |
| Return on Assets (ROA) | -45.0% | -91.6% | -111.9% | -302.2% | -220.6% | -197.1% | -364.9% | -1363.9% |
| Current Ratio | 0.11x | 0.30x | 0.06x | 1.66x | 3.07x | 2.78x | 1.44x | 0.22x |
| Quick Ratio | 0.03x | 0.13x | 0.04x | 1.07x | 2.85x | 2.53x | 1.25x | 0.09x |
| Debt to Equity | 0.01x | 0.06x | 0.10x | 0.18x | 0.07x | 0.09x | 0.42x | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
